1 - 25 of 63 results for author:"Bernards R." in Literature citations
Results Customize
› Repeat search in UniProtKB (45)
| An alpha-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. Majewski I.J., Kluijt I., Cats A., Scerri T.S., de Jong D., Kluin R.J., Hansford S., Hogervorst F.B., Bosma A.J., Hofland I. et al. J. Pathol. 229:621-629(2013) · Mapped (8) |
| MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling. Huang S., Holzel M., Knijnenburg T., Schlicker A., Roepman P., McDermott U., Garnett M., Grernrum W., Sun C., Prahallad A. et al. Cell 151:937-950(2012) · Mapped (14) |
| USP15 stabilizes TGF-beta receptor I and promotes oncogenesis through the activation of TGF-beta signaling in glioblastoma. Eichhorn P.J., Rodon L., Gonzalez-Junca A., Dirac A., Gili M., Martinez-Saez E., Aura C., Barba I., Peg V., Prat A. et al. |
| Identification of F-box only protein 7 as a negative regulator of NF-kappaB signalling. Kuiken H.J., Egan D.A., Laman H., Bernards R., Beijersbergen R.L., Dirac A.M. J. Cell. Mol. Med. 16:2140-2149(2012) · Mapped (3) |
| The cocaine- and amphetamine-regulated transcript mediates ligand-independent activation of ERalpha, and is an independent prognostic factor in node-negative breast cancer. Brennan D.J., O'Connor D.P., Laursen H., McGee S.F., McCarthy S., Zagozdzon R., Rexhepaj E., Culhane A.C., Martin F.M., Duffy M.J. et al. Oncogene 31:3483-3494(2012) · Mapped (57) |
| The histone demethylase Jarid1b (Kdm5b) is a novel component of the Rb pathway and associates with E2f-target genes in MEFs during senescence. Nijwening J.H., Geutjes E.J., Bernards R., Beijersbergen R.L. PLoS ONE 6:e25235-e25235(2011) · Mapped (4) |
| TSPYL5 suppresses p53 levels and function by physical interaction with USP7. Epping M.T., Meijer L.A., Krijgsman O., Bos J.L., Pandolfi P.P., Bernards R. Nat. Cell Biol. 13:102-108(2011) · UniProtKB (2) · Mapped (6) |
| The translation initiation factor 3f (eIF3f) exhibits a deubiquitinase activity regulating Notch activation. Moretti J., Chastagner P., Gastaldello S., Heuss S.F., Dirac A.M., Bernards R., Masucci M.G., Israel A., Brou C. PLoS Biol. 8:E1000545-E1000545(2010) · UniProtKB (2) · Mapped (3) |
| NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Holzel M., Huang S., Koster J., Ora I., Lakeman A., Caron H., Nijkamp W., Xie J., Callens T., Asgharzadeh S. et al. Cell 142:218-229(2010) · Mapped (10) |
| The deubiquitinating enzyme USP26 is a regulator of androgen receptor signaling. Dirac A.M., Bernards R. Mol. Cancer Res. 8:844-854(2010) · UniProtKB (2) · Mapped (2) |
| Interleukin-1R-associated kinase 2 is a novel modulator of the transforming growth factor beta signaling cascade. Mullenders J., Fabius A.W., van Dongen M.M., Kuiken H.J., Beijersbergen R.L., Bernards R. Mol. Cancer Res. 8:592-603(2010) · Mapped (11) |
| Candidate biomarkers of response to an experimental cancer drug identified through a large-scale RNA interference genetic screen. Mullenders J., von der Saal W., van Dongen M.M., Reiff U., van Willigen R., Beijersbergen R.L., Tiefenthaler G., Klein C., Bernards R. Clin. Cancer Res. 15:5811-5819(2009) · Mapped (7) |
| ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Huang S., Laoukili J., Epping M.T., Koster J., Holzel M., Westerman B.A., Nijkamp W., Hata A., Asgharzadeh S., Seeger R.C. et al. Cancer Cell 15:328-340(2009) · Mapped (8) |
| A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. Mullenders J., Fabius A.W., Madiredjo M., Bernards R., Beijersbergen R.L. PLoS ONE 4:e4798-e4798(2009) · Mapped (52) |
| Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1. Herold S., Hock A., Herkert B., Berns K., Mullenders J., Beijersbergen R., Bernards R., Eilers M. EMBO J. 27:2851-2861(2008) · Mapped (21) |
| Suppression of the p53-dependent replicative senescence response by lysophosphatidic acid signaling. Kortlever R.M., Brummelkamp T.R., van Meeteren L.A., Moolenaar W.H., Bernards R. Mol. Cancer Res. 6:1452-1460(2008) · Mapped (2) |
| An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Stemke-Hale K., Gonzalez-Angulo A.M., Lluch A., Neve R.M., Kuo W.L., Davies M., Carey M., Hu Z., Guan Y., Sahin A. et al. Cancer Res. 68:6084-6091(2008) · Mapped (15) |
| PRAME expression and clinical outcome of breast cancer. Epping M.T., Hart A.A., Glas A.M., Krijgsman O., Bernards R. Br. J. Cancer 99:398-403(2008) · Mapped (5) |
| Transforming growth factor-beta requires its target plasminogen activator inhibitor-1 for cytostatic activity. Kortlever R.M., Nijwening J.H., Bernards R. J. Biol. Chem. 283:24308-24313(2008) · Mapped (8) |
| A RNA interference screen identifies the protein phosphatase 2A subunit PR55gamma as a stress-sensitive inhibitor of c-SRC. Eichhorn P.J., Creyghton M.P., Wilhelmsen K., van Dam H., Bernards R. PLoS Genet. 3:e218-e218(2007) · Mapped (3) |
| A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors. Epping M.T., Wang L., Plumb J.A., Lieb M., Gronemeyer H., Brown R., Bernards R. Proc. Natl. Acad. Sci. U.S.A. 104:17777-17782(2007) · Mapped (5) |
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M. et al. Cancer Cell 12:395-402(2007) · Mapped (10) |
| The ubiquitin-specific protease USP28 is required for MYC stability. Popov N., Wanzel M., Madiredjo M., Zhang D., Beijersbergen R., Bernards R., Moll R., Elledge S.J., Eilers M. Nat. Cell Biol. 9:765-774(2007) · UniProtKB (3) · Mapped (11) |
| A functional genetic screen identifies TFE3 as a gene that confers resistance to the anti-proliferative effects of the retinoblastoma protein and transforming growth factor-beta. Nijman S.M., Hijmans E.M., El Messaoudi S., van Dongen M.M., Sardet C., Bernards R. J. Biol. Chem. 281:21582-21587(2006) · Mapped (3) |
| PR130 is a modulator of the Wnt-signaling cascade that counters repression of the antagonist Naked cuticle. Creyghton M.P., Roeel G., Eichhorn P.J.A., Vredeveld L.C., Destree O., Bernards R. Proc. Natl. Acad. Sci. U.S.A. 103:5397-5402(2006) · UniProtKB (1) |